Facebook Linkedin RSS Twitter Youtube
Home 2024

Prime Medicine

eePASSIGE Engineers Gene-Sized Edits in Human Cells 
Genome Editing

eePASSIGE Engineers Gene-Sized Edits in Human Cells 

Top 10 Publicly Owned Gene Editing Therapy Companies
A-Lists

Top 10 Publicly Owned Gene Editing Therapy Companies

FDA Clears Prime Medicine’s IND for First Prime Editing Therapy
Genome Editing

FDA Clears Prime Medicine’s IND for First Prime Editing Therapy

StockWatch: Nvidia Jumps 24% on Recursion, Amgen AI Partnerships
Artificial Intelligence

StockWatch: Nvidia Jumps 24% on Recursion, Amgen AI Partnerships

JPM: Prime Medicine Eyes 2024 IND for First Prime Editing Therapy
GEN Edge

JPM: Prime Medicine Eyes 2024 IND for First Prime Editing Therapy

The Next Chapter in Genome Editing? Tome Emerges from Stealth with $213M
GEN Edge

The Next Chapter in Genome Editing? Tome Emerges from Stealth with $213M

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar
GEN Edge

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar

At Chardan Conference, David Liu Foresees First Prime Editing Clinical Trial in 2024
GEN Edge

At Chardan Conference, David Liu Foresees First Prime Editing Clinical Trial in 2024

Base Editors and Prime Editors Begin to Realize Their Clinical Promise
Genome Editing

Base Editors and Prime Editors Begin to Realize Their Clinical Promise

Search and Replace: Andrew Anzalone Details How Genome Editing Went Prime Time on “Close to the Edge”
Close to the Edge

Search and Replace: Andrew Anzalone Details How Genome Editing Went Prime Time on “Close to the Edge”

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.